Wechselwirkungen · Nimenrix
Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine · Abschnitt 4.5 · PDF-Seite 5
HOS-213759 · Präparat HOS-155198
One month after co-administration with a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed (Tdap) in subjects aged 9 to 25 years, lower GMCs were observed to each pertussis antigen (pertussis toxoid [PT], filamentous haemagglutinin [FHA] and pertactin [PRN]). More than 98% of subjects had anti-PT, FHA or PRN concentrations above the assay cut-off thresholds. The clinical relevance of these observations is unknown. There was no
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pertussis vaccine (HOS-115105)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-13T13:10:00Z · SHA-256 47ca5a942f5fe1d6ee76efb76a4a7dbc6147fbdb447af3923eb0bf5adf5d0d4d · Passage d858d42b4208a5c33ee813b58f9dc91139815928035f728c91fc5b1c5cd64a5b · Zeichen 1620–2093 im Abschnitt